Leede Financial Trims Sernova (TSE:SVA) Target Price to C$1.50

Sernova (TSE:SVA) had its target price lowered by Leede Financial from C$3.00 to C$1.50 in a research note published on Friday, BayStreet.CA reports. The brokerage currently has a speculative buy rating on the stock. Leede Financial also issued estimates for Sernova’s FY2027 earnings at ($0.02) EPS.

Sernova Price Performance

Shares of TSE SVA opened at C$0.26 on Friday. The stock has a market cap of C$82.72 million, a price-to-earnings ratio of -1.96 and a beta of 1.38. Sernova has a 52 week low of C$0.20 and a 52 week high of C$0.83. The company’s 50-day moving average price is C$0.27 and its 200 day moving average price is C$0.37. The company has a current ratio of 0.62, a quick ratio of 18.11 and a debt-to-equity ratio of 16.55.

Sernova (TSE:SVA) last issued its quarterly earnings data on Friday, June 14th. The company reported C($0.03) EPS for the quarter, meeting analysts’ consensus estimates of C($0.03). As a group, research analysts forecast that Sernova will post -0.08 earnings per share for the current fiscal year.

Insider Activity at Sernova

In related news, Director Steven Sangha sold 930,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of C$0.24, for a total value of C$223,200.00. In the last three months, insiders have acquired 359,600 shares of company stock valued at $92,771. Insiders own 12.98% of the company’s stock.

About Sernova

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.